A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Infectious Diseases

• Publication date

  2004-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/423377PMID 15472817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines for treatment of candidiasis.

  2004cited by this paper
• Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

  2004cited by this paper
• Invasive oesophageal candidiasis: current and developing treatment options.

  2003cited by this paper
• Echinocandin antifungal drugs.

  2003cited by this paper
• Echinocandins: a new class of antifungal.

  2002cited by this paper
• Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with Caspofungin

  2002cited by this paper
• A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.

  2002cited by this paper
• In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.

  2002cited by this paper
• Antifungal use in HIV infection

  2002cited by this paper
• A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.

  2001cited by this paper
• In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi

  2000cited by this paper
• Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.

  2000cited by this paper
• Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study.

  1999cited by this paper
• Options for the Management of Mucosal Candidiasis in Patients with AIDS and HIV Infection

  1999cited by this paper
• In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

  1997cited by this paper
• A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis.

  1997cited by this paper
• Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study.

  1995cited by this paper
• Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study.

  1995cited by this paper
• Fluconazole Compared with Ketoconazole for the Treatment of Candida Esophagitis in AIDS

  1992cited by this paper
• Candida esophagitis: a prospective study of 27 cases.

  1976cited by this paper
• Tests for Linear Trends in Proportions and Frequencies

  1955cited by this paper
• A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES

  1954cited by this paper
• Some Methods for Strengthening the Common χ 2 Tests

  1954cited by this paper
• The asymptotic normality and consistency of kendall's test against trend, when ties are present in one ranking

  1952cited by this paper

• Invasive Gastric Candidiasis With Concurrent Clostridioides difficile Colitis: A Case Report and Review of the Literature

  2025cites this paper
• Bridging Echinocandin With Azole Antifungal Therapy on Prevention of Invasive Candidiasis Post–Lung Transplantation

  2024cites this paper
• Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review

  2023cites this paper
• Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review

  2023cites this paper
• Systemic anti-fungal therapy for esophageal candidiasis - systematic review and meta-analysis of randomized controlled trials.

  2022cites this paper
• Echinocandins

  2021cites this paper
• HPLC-MS identification and expression of Candida drug-resistance proteins from African HIV-infected patients

  2021cites this paper
• Efficacy and acceptability of different anti-fungal interventions in oropharyngeal or esophageal candidiasis in HIV co-infected adults: a pilot network meta-analysis

  2021cites this paper
• The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections

  2020cites this paper
• Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

  2020cites this paper
• Incidence and spectrum of yeast species isolated from the oral cavity of Iranian patients suffering from hematological malignancies

  2019cites this paper
• British HIV Association/British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019

  2019cites this paper
• Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cites this paper
• We can do better: a fresh look at echinocandin dosing.

  2018cites this paper
• Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

  2018cites this paper
• Echinocandins in antifungal pharmacotherapy

  2017cites this paper
• Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

  2017cites this paper
• Formación médica continuada: Infección fúngica invasora Candidemia y candidiasis invasora en el adulto. Formas clínicas y tratamiento

  2016cites this paper
• Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

  2016cites this paper
• Enfermedades Infecciosas y Microbiología Clínica

  2016cites this paper
• The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections

  2016cites this paper
• Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.

  2016cites this paper
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

  2016cites this paper
• Synthesis and characterization of caffeic acid and dihydrocaffeic acid derivatives as antifungal agents

  2016cites this paper
• Lipopeptides: Status and Strategies to Control Fungal Infection

  2016cites this paper
• Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces.

  2015cites this paper
• A n t i f u n g a l A g e n t s Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• Testing of the antifungal activity of oleylphosphocholine on Candida albicans planktonic cells and biofilms developed in vitro and in vivo in a subcutaneous biofilm model

  2015cites this paper
• Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis

  2015cites this paper
• Classifying drugs in pregnancy

  2014cites this paper
• Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis

  2014cites this paper
• Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013

  2014cites this paper
• Tissue Penetration of Antifungal Agents

  2014cites this paper
• Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato‐oncological high‐risk patients: a web‐based non‐interventional trial in four large university hospitals in Germany

  2014cites this paper
• Micafungin: an evidence-based review of its place in therapy

  2014cites this paper
• Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs

  2014cites this paper
• Recent advances in the treatment of life-threatening, invasive fungal infections

  2013cites this paper
• Clinical study on anti-fungal drug activity against clinically isolated strains of oral Candida species

  2013cites this paper
• Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents

  2013cites this paper
• ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS.

  2012cites this paper
• Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis

  2012influential citation
• Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.

  2012cites this paper
• A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis

  2012cites this paper
• Fungal infection in solid organ recipients.

  2012cites this paper
• Brazilian guidelines for the management of candidiasis – a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical

  2012cites this paper
• Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders

  2012cites this paper
• ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).

  2012cites this paper
• Advances in systemic antifungal therapy.

  2012cites this paper
• [Candidemia and invasive candidiasis in the adult: clinical forms and treatment].

  2012cites this paper
• Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders

  2012cites this paper
• Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy –status quo

  2012cites this paper
• Candida albicans induces monocyte training via epigenetic reprogramming through a dectin-1-dependent pathway

  2012cites this paper
• Esophagitis in the Immunocompromised Host

  2012cites this paper
• 3. TDM of Antifungal Agents: Is it Necessary?

  2012cites this paper
• 339 – Systemic Antifungal Agents

  2012cites this paper
• Micafungin Review of its Use in the Prophylaxis and Treatment of

  2012cites this paper
• Chapter 28 – Candida in HIV infection

  2012cites this paper
• Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIVinfected Koreans

  2012cites this paper
• Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use

  2012cites this paper
• Micafungin for candidiasis

  2012cites this paper
• RECENT DEVELOPMENTS IN ANTIFUNGAL AGENTS Review Article

  2012cites this paper
• Micafungin

  2012cites this paper
• Micafungin

  2012cites this paper
• RECENT DEVELOPMENTS IN ANTIFUNGAL AGENTS

  2012cites this paper
• Safety of micafungin in prospective and retrospective clinical trials

  2012cites this paper
• Evolving controversies and challenges in the management of opportunistic infections in HIV-seropositive individuals.

  2011cites this paper
• Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

  2011cites this paper
• Overview of treatment options for invasive fungal infections.

  2011cites this paper
• Antifungal Use for Opportunistic Infection in HIV Patients: Comparison of Efficacy and Safety

  2011cites this paper
• Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins

  2011cites this paper
• Mucocutaneous and Deeply Invasive Candidiasis

  2011cites this paper
• [Liver toxicity of micafungin. Is this drug safe?].

  2011cites this paper
• [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].

  2011cites this paper
• Toxicidad hepática de micafungina. ¿Es micafungina un fármaco seguro?

  2011cites this paper
• 7 Candidiasis

  2011cites this paper
• Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report

  2011influential citation
• Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

  2011cites this paper
• Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul‐Ehrlich‐Society for Chemotherapy

  2011cites this paper
• [Echinocandins].

  2011cites this paper
• Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study.

  2011cites this paper
• Safety of micafungin in infants: insights into optimal dosing

  2011cites this paper
• Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature

  2011cites this paper
• Transcriptional regulation of azole antifungal resistance and tolerance in Candida glabrata

  2010cites this paper
• Interactions between antifungal and antiretroviral agents

  2010cites this paper
• Intrapulmonary Pharmacokinetics and Pharmacodynamics of Micafungin in Adult Lung Transplant Patients

  2010cites this paper
• Traditional and emerging antifungal therapies.

  2010cites this paper
• The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis

  2010cites this paper
• Therapy for fungal diseases: opportunities and priorities.

  2010cites this paper
• Antifungals to treat Candida albicans

  2010cites this paper
• Echinocandins: A ray of hope in antifungal drug therapy

  2010cites this paper
• Oropharyngeal candidiasis in the era of antiretroviral therapy.

  2010cites this paper
• Novel, broad-specrum antimycotic agents: the role of echinocandins today

  2010cites this paper
• Echinocandin pharmacodynamics: review and clinical implications.

  2010cites this paper
• Analysis of Candida glabrata strains with reduced sensitivity to micafungin in vitro isolated from a patient with persistent Candidemia.

  2010cites this paper
• Opportunistic infections in HIV disease.

  2010cites this paper
• Echinocandins – Caspofungin, Anidulafungin and Micafungin

  2010cites this paper
• antimycotic agents: the role of echinocandins today

  2010cites this paper
• Micafungin in a nutshell: state of affairs on the pharmacological and clinical aspects of the novel echinocandin

  2010cites this paper
• CHAPTER 19 – Fungal infections in the patient with human immunodeficiency virus infection

  2009cites this paper